Scalper1 News
Small biotech Amicus Therapeutics (FOLD) jumped more than 30% Thursday after the company said it would file for accelerated approval of its lead drug candidate after positive meetings with the FDA and EU authorities. Amicus’ drug migalastat would be the first oral treatment for Fabry disease, a rare but serious congenital condition currently treated with the IV drugs Fabrazyme (from Sanofi (SNY) and Replagal (from Shire (SHPG). Amicus said that Scalper1 News
Scalper1 News